NPPB and chronic kidney disease: Last, although the HARP-III population is patients with preexisting chronic kidney disease, about 3.6% (15/414) of them self-reported history of heart failure; however, the average baseline NT pro-BNP level was lower than the inclusion criteria of the PARADIGM and PARAGON trials (254.5 ng/L in the sacubitril/valsartan group and 250.9 ng/L in the irbesartan group, respectively) (UK HARP-III Collaborative Group, 2017).